{"id":37858,"date":"2025-07-24T12:15:04","date_gmt":"2025-07-24T04:15:04","guid":{"rendered":"https:\/\/flcube.com\/?p=37858"},"modified":"2025-07-24T12:15:05","modified_gmt":"2025-07-24T04:15:05","slug":"kintors-kx-826-topical-solution-meets-primary-endpoint-in-aga-phase-ii-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37858","title":{"rendered":"Kintor’s KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial"},"content":{"rendered":"\n

China-based Kintor Pharmaceutical (HKG: 9939<\/a>) announced on July 24, 2025, that its self-developed 1.0% KX-826 topical solution has achieved its primary endpoint in a pivotal Phase II clinical trial for the treatment of androgenetic alopecia (AGA) in adult Chinese males. The results demonstrated both statistical significance and clinical relevance, alongside good safety and tolerability.<\/p>\n\n\n\n

Clinical Trial Design and Results<\/strong>
This adaptive Phase II\/III trial was a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of KX-826 topical solution at 0.5% and 1.0% concentrations. The Phase II stage enrolled 90 subjects who underwent a 24-week treatment period followed by a one-month safety observation. Results showed that both the 0.5% and 1.0% groups achieved statistically significant improvements in key efficacy indicators, including Target Area Hair Count (TAHC) and Investigator Global Assessment of Hair Growth (HGA), compared to the placebo group. Specifically, the 0.5% BID group saw a TAHC increase of 13.66 hairs\/cm\u00b2, while the 1.0% BID group increased by 13.14 hairs\/cm\u00b2. Both groups also showed clear superiority over placebo in HGA.<\/p>\n\n\n\n

Safety Profile<\/strong>
Regarding safety, KX-826 exhibited a low incidence of overall adverse events, with no drug-related sexual dysfunction or new safety signals observed. This underscores the favorable safety and tolerability profile of the drug.<\/p>\n\n\n\n

Future Trial Plans<\/strong>
The independent data monitoring committee (IDMC) recommended proceeding with the Phase III stage as originally designed. KX-826 is a potential first-in-class topical AR antagonist.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Kintor Pharmaceutical (HKG: 9939) announced on July 24, 2025, that its self-developed 1.0% KX-826…<\/p>\n","protected":false},"author":1,"featured_media":37859,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,958,547],"class_list":["post-37858","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-hkg-9939","tag-kintor-pharmaceutical"],"yoast_head":"\nKintor's KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Kintor Pharmaceutical (HKG: 9939) announced on July 24, 2025, that its self-developed 1.0% KX-826 topical solution has achieved its primary endpoint in a pivotal Phase II clinical trial for the treatment of androgenetic alopecia (AGA) in adult Chinese males. The results demonstrated both statistical significance and clinical relevance, alongside good safety and tolerability.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37858\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kintor's KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial\" \/>\n<meta property=\"og:description\" content=\"China-based Kintor Pharmaceutical (HKG: 9939) announced on July 24, 2025, that its self-developed 1.0% KX-826 topical solution has achieved its primary endpoint in a pivotal Phase II clinical trial for the treatment of androgenetic alopecia (AGA) in adult Chinese males. The results demonstrated both statistical significance and clinical relevance, alongside good safety and tolerability.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37858\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-24T04:15:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-24T04:15:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2401.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37858#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37858\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kintor’s KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial\",\"datePublished\":\"2025-07-24T04:15:04+00:00\",\"dateModified\":\"2025-07-24T04:15:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37858\"},\"wordCount\":241,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37858#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2401.webp\",\"keywords\":[\"Clinical trial results\",\"HKG: 9939\",\"Kintor Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37858#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37858\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37858\",\"name\":\"Kintor's KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37858#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37858#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2401.webp\",\"datePublished\":\"2025-07-24T04:15:04+00:00\",\"dateModified\":\"2025-07-24T04:15:05+00:00\",\"description\":\"China-based Kintor Pharmaceutical (HKG: 9939) announced on July 24, 2025, that its self-developed 1.0% KX-826 topical solution has achieved its primary endpoint in a pivotal Phase II clinical trial for the treatment of androgenetic alopecia (AGA) in adult Chinese males. The results demonstrated both statistical significance and clinical relevance, alongside good safety and tolerability.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37858#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37858\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37858#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2401.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2401.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kintor's KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37858#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kintor’s KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kintor's KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial - Insight, China's Pharmaceutical Industry","description":"China-based Kintor Pharmaceutical (HKG: 9939) announced on July 24, 2025, that its self-developed 1.0% KX-826 topical solution has achieved its primary endpoint in a pivotal Phase II clinical trial for the treatment of androgenetic alopecia (AGA) in adult Chinese males. The results demonstrated both statistical significance and clinical relevance, alongside good safety and tolerability.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37858","og_locale":"en_US","og_type":"article","og_title":"Kintor's KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial","og_description":"China-based Kintor Pharmaceutical (HKG: 9939) announced on July 24, 2025, that its self-developed 1.0% KX-826 topical solution has achieved its primary endpoint in a pivotal Phase II clinical trial for the treatment of androgenetic alopecia (AGA) in adult Chinese males. The results demonstrated both statistical significance and clinical relevance, alongside good safety and tolerability.","og_url":"https:\/\/flcube.com\/?p=37858","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-24T04:15:04+00:00","article_modified_time":"2025-07-24T04:15:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2401.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37858#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37858"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kintor’s KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial","datePublished":"2025-07-24T04:15:04+00:00","dateModified":"2025-07-24T04:15:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37858"},"wordCount":241,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37858#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2401.webp","keywords":["Clinical trial results","HKG: 9939","Kintor Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37858#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37858","url":"https:\/\/flcube.com\/?p=37858","name":"Kintor's KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37858#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37858#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2401.webp","datePublished":"2025-07-24T04:15:04+00:00","dateModified":"2025-07-24T04:15:05+00:00","description":"China-based Kintor Pharmaceutical (HKG: 9939) announced on July 24, 2025, that its self-developed 1.0% KX-826 topical solution has achieved its primary endpoint in a pivotal Phase II clinical trial for the treatment of androgenetic alopecia (AGA) in adult Chinese males. The results demonstrated both statistical significance and clinical relevance, alongside good safety and tolerability.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37858#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37858"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37858#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2401.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2401.webp","width":1080,"height":608,"caption":"Kintor's KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37858#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kintor’s KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2401.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37858"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37858\/revisions"}],"predecessor-version":[{"id":37860,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37858\/revisions\/37860"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37859"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}